α-synuclein aggregation and Parkinson's disease: Factors affecting the aggregation of α-synuclein

Progress in Biochemistry and Biophysics

Volumn 33, Issue 4, 2006, Pages 321-328

  Jin, Ling ^a   Yang, Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

synuclein; Lewy bodies; Parkinson's disease

Indexed keywords

EID: 33745992301     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Maroteaux L, Campanelli J T, Scheller R H. Synuclein:a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 1988, 8 (8): 2804-2815
2. Conway K A, Lee S J, Rochet J C, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA, 2000, 97 (2): 571-576
3. Kessler J C, Rochet J C, Lansbury P T Jr, et al. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry, 2003, 42 (3): 672-678
4. Bodies A M, Guthrie D J, Harriott P, et al. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur J Biochem, 2000, 267 (8): 2186-2194
5. Giasson B I, Murray I V, Trojanowski J Q, et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem, 2001, 276 (4): 2380-2386
6. Du H N, Tang L, Luo X Y, et al. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry, 2003, 42(29): 8870-8878
7. Murray I V, Giasson B I, Quinn S M, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry, 2003, 42 (28): 8530-8540
8. Uversky V N, Li J, Fink A L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem, 2001, 276 (14): 10737-10744
9. Uversky V N, Li J, Fink A L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett, 2001, 500 (3): 105-108
10. Uversky V N, Li J, Fink A L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. J Biol Chem, 2001, 276 (47): 44284-44296
11. Yamin G, Glaser C B, Uversky V N, et al. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem, 2003, 278 (30): 27630-27635
12. 2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem, 2001, 276 (25): 22680-22684
13. Golts N, Snyder H, Frasier M, et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem, 2002, 277 (18): 16116-16123
14. McNaught K S, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem, 2002, 81 (2): 301-306
15. Rideout H J, Larsen K E, Sulzer D, et al. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein immunoreactive inclusions in PC12 cells. J Neurochem, 2001, 78 (4): 899-908
16. Liu C W, Giasson B I, Lewis K A, et al. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation:implications for pathogenesis of Parkinson disease. J Biol Chem, 2005, 280 (24): 22670-22678
17. Hashimoto M, Takeda A, Hsu L J, et al. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem, 1999, 274 (41): 28849-28852
18. Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet, 1999, 22 (1): 110-114
19. Cole N B, Murphy D D, Lebowitz J, et al. Metal-catalyzed oxidation of alpha-synuclein:helping to define the relationship between oligomers, protofibrils and filaments. J Biol Chem, 2005, 280 (10): 9678-9690
20. Uversky V N, Yamin G, Souillac P O, et al. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett, 2002, 517 (1-3): 239-244
21. Norris E H, Giasson B I, Ischiropoulos H, et al. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem, 2003, 278 (29): 27230-27240
22. Hodara R, Norris E H, Giasson B I, et al. Functional consequences of alpha-synuclein tyrosine nitration:diminished binding to lipid vesicles and increased fibril formation. J Biol Chem, 2004, 279 (46): 47746-47753
23. Lee H J, Choi C, Lee S J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem, 2002, 277 (1): 671-678
24. Zhu M, Fink A L. Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem, 2003, 278 (19): 16873-16877
25. Klucken J, Shin Y, Masliah E, et al. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem, 2004, 279 (24): 25497-25502
26. Dedmon M M, Christodoulou J, Wilson M R, et al. Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem, 2005, 280 (15): 14733-14740
27. Uversky V N, Li J, Souillac P, et al. Biophysical Properties of the synucleins and their propensities to fibrillate:inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem, 2002, 277 (14): 11970-11978
28. Conway K A, Rochet J C, Bieganski R M, et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 2001, 294 (5545): 1346-1349
29. Volles M J, Lee S J, Rochet J C, et al. Vesicle permeabilization by protofibrillar alpha-synuclein:implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 2001, 40 (26): 7812-7819
30. Li J, Zhu M, Rajamani S, et al. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol, 2004, 11(11): 1513-1521
31. McLean P J, Klucken J, Shin Y, et al. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity In vitro. Biochem Biophys Res Commun, 2004, 321 (3): 665-669
32. Volles M J, Lansbury P T Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry, 2002, 41 (14): 4595-4602